Lipid metabolic enzymes: emerging drug targets for the treatment of obesity.
Shi
Yuguang
Y
Endocrine Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
Burn
Paul
P
D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D004041:Dietary Fats / Q000378:metabolism*; D004063:Digestion; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007783:Lactones / Q000627:therapeutic use; D008049:Lipase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D050356:Lipid Metabolism; D009765:Obesity / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D000077403:Orlistat
D019440:Anti-Obesity Agents; D004041:Dietary Fats; D004791:Enzyme Inhibitors; D007783:Lactones; D000077403:Orlistat; D008049:Lipase